Eye Injection Drugs on Medicare: Eylea, Lucentis, and Avastin

If you have wet macular degeneration, diabetic retinopathy, or a retinal vein occlusion, there is a good chance your treatment involves an injection into the eye given by your retina specialist. These anti-VEGF drugs, Eylea, Lucentis, and the much cheaper off-label option Avastin, can protect your vision, but the way Medicare covers them surprises many people. Because a doctor administers them in the office, they fall under Part B rather than your Part D drug plan, and that changes what you pay. The choice of drug also has a striking effect on cost, which is worth understanding before your treatment plan is set.

Bryce's Take

Eye injections catch people off guard twice: first because they run under Part B instead of Part D, and second because the drug choice swings the cost so dramatically. I have had clients on monthly injections where a good Medigap plan meant they paid almost nothing, and others on Advantage plans where the out-of-pocket maximum was doing the heavy lifting. If you are getting regular anti-VEGF injections, let us make sure your coverage handles that 20 percent, because over a year of treatment it genuinely matters.

Why these drugs fall under Part B

Eye injections are not something you do yourself at home. Your ophthalmologist or retina specialist administers the injection directly into the eye during an office visit. Because the drug is provider-administered in a clinical setting, Medicare covers it under Part B, the medical side, not under Part D. That means these drugs run through the buy-and-bill model, where the provider obtains the drug, injects it, and bills Medicare for both the drug and the procedure. Your drug plan is not involved.

What Part B coverage costs you

Under Original Medicare, after you meet the annual Part B deductible, you generally pay 20 percent coinsurance for these injections. Because you may need injections repeatedly, sometimes monthly for a stretch, that 20 percent can add up over a year, and Original Medicare on its own places no annual cap on it. A comprehensive Medigap plan like Plan G generally covers the 20 percent coinsurance, which can bring your cost close to zero after the deductible. Under a Medicare Advantage plan, the cost-sharing runs through the plan and counts toward its annual out-of-pocket maximum.

Eylea, Lucentis, and Avastin: the cost gap

The three most common anti-VEGF drugs differ enormously in price. Eylea and Lucentis are branded drugs developed and priced specifically for eye conditions, and they carry high list prices per dose. Avastin is a cancer drug that ophthalmologists use off-label for retinal conditions, and because a single vial can be divided into many individual eye doses, the cost per injection is a small fraction of the branded alternatives. For many patients, studies have supported Avastin as clinically effective for these conditions, which is why it is so widely used despite being off-label.

The three drugs at a glance

Why doctors and plans may prefer Avastin

Because your coinsurance is a percentage of the drug's cost, a cheaper drug means a smaller bill for you as well as for Medicare. Many retina specialists start with Avastin and reserve the branded drugs for patients who do not respond as well, both because Avastin performs comparably for many patients and because it costs so much less. Some Medicare Advantage plans and utilization rules also encourage trying the lower-cost option first. That said, the right drug is a medical decision between you and your specialist, since some conditions or patients respond better to Eylea or Lucentis.

What this means for your coverage choice

If you are facing ongoing eye injections, the cost that lands on you depends on which drug you receive and how your supplemental coverage handles the 20 percent Part B coinsurance. A strong Medigap plan can nearly erase your share of even the expensive branded drugs, while an Advantage plan caps your annual exposure through its out-of-pocket maximum. Your exact costs depend on your drug, your treatment frequency, and your coverage, so it is worth looking at your specific situation rather than assuming.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.